Original Article

Prognostic Significance of CONUT Score in Elderly NSCLC

m'r _ _ r m m

Purpose: This study evaluated the Controlling Nutritional Status (CONUT) score as a prognostic predictor in elderly non-small cell lung cancer (NSCLC) patients with surgical resection.

Methods: Overall, 114 patients over 80 years old undergoing curative resection for NSCLC were retrospectively analyzed. Receiver operating characteristic (ROC) analysis was conducted to evaluate the capacity of immune-inflammatory markers to predict overall survival (OS). Cox-proportional hazards regression analysis was implemented to investigate prognostic markers for OS.

Results: Based on ROC curves, the CONUT score was found to be the most valuable prognostic marker (area under the curve = 0.716). The high CONUT (≥ 2) group included 54 patients, and the low CONUT (0 or 1) group included 60 patients. The high CONUT group had poorer prognosis rates compared to the low CONUT group with regard to OS (5-year OS: 46.3% vs. 86.0%, p = 0.0006). In the multivariate data analysis, histology, lymphatic invasion, and CONUT score (hazard ratio: 4.23, p = 0.0003) were found to be exclusive and independent prognostic markers for OS.

Conclusion: Preoperatively, the CONUT score can be used as a novel prognostic marker in elderly NSCLC patients. CONUT evaluations can also be used to design nutritional interventions to improve patient outcomes.

Keywords:

m. f mm r r

Abbreviations and Acronyms

```
rmrm
mefmmrr
rer
rrer
```

Department of Thoracic Surgery, Kochi Medical School, Nankoku, Kochi, Japan



cardiovascular Surgery f Annals of Thoracic and

m r , m r m m m r r r , r r m ¢ (r. 6 r r • , r r , m_r m m r r m , m m 6 m r , r • r • r r r r r s, r , r r efe , r r • rr • fr , r

, r.

r

• r

Introduction

• rr r. , r_ rr. • r m mm , r r. 6 • rf /mrm.•r r rr, ff r m m. fmm rr r • • r 6<u>[</u>7 6_ 6 6 <u>f</u> • r r.r m m

r • r _ / r _ r• r • r m_•_fmm_rmrr_•/ m • r • r , r fr_ fmm_mrr_•, r _ m • r _ _ r 🕻 r _ , m _ r _ m 6 r m • r _ r _ m • r _ _ m • r _ _ r r r _ , . . . r . _ -

_ • r r____r ′____ ___ ¢ r • • rf • mm, r f 🗣 f , , , r ſ____ſ_€€.__ r r r r mm fr r_r___rfrr fr r . . . rrr rr f. r . m f m • m r . . fr . _ • • m _ _ f _ f m r_rm_ , mrmrre...r.er. r frrrr

f 'r r • • r _ r _• _ · • m fr r _ m • ' . • • r _ _ · • m fr r _ m • r • _ r · • • r _ _ · r _ r _ f mm r mr r · • _ _ r • r _ r _ mm r

, m r

Materials and Methods

Study design

r• r , m r • r 66 <u>r</u> 6 6 , 6 _ r f . mm f 6 6 . • r _ r m . . m frm r 6 , f rr • rfr. • r

Patients

•m r _r m , r r m r • • • · · · · • m r m rr. « r « f r s s , r . r _ • _ 6 6 67 err r , r r 🖕 r 6 r r m, r • • r. r. r m . f, c f • r r m___. r « rfr« « fr. 6 . _ _ m _ _ r r _ _ _ _ • _ • _ • _ r r r r _____rm_f_rr___rm_rre rm m r m

Data collection and follow-up

<u>т</u> п. с г с п. . . с п . c. r. c. m. c mrm m **s**rr , r _ _ _ r m r rrr fr m . r r ¢r_¢ r 🛭 r 6 r _ / r f , _ r., r _• m r r_m ,r_. 6 fr r frr m r m , • f m.r 6 m r rf rm • r _ • _ • rrr • • r • r •

Calculation of immune-inflammatory markers

_ m . _ / m ¢ • r m rr___rm_r___¢r r r f n'm 'm 6 6, rfr_m rf m• _--6 m • Table 1• rr rm • r rm, meer 1 . . r r m • • , Table 2

mrr	r f	mrrfrm/
_ • r	r _ , , r , • r	srTable 2
	Г., С. / Г.,	/ m_ / m_ • / _
	Γ. Γ. 6 / Γ	/ M
		an a
-	r • _ r _ m • r _	r • _ m _ m • _
	r•_rrm_r_	r • _ r _ m, _ , _
-	m, _, , m, m •	m, _ m • !_ , m , _ !_
-	r mer	, r _ !_ m • !_
-	m • r	m •
	, m_ r	·
	, r _ , m _ r _	, r , m

 Table 1
 Abbreviations and biomarker formulas of various factors

Table 2The CONUT scoring system

-	_ f / f _ /						
Ι_	rm	*	r	r			
r/m /m_ /	2		_				
¢ r							
m 🔹 🛀 mm-	\geq	_	_				
¢ []							
• r m	\geq	-					
¢ r							
_ • ľ	-	-	-	-			

_ r _ , , r__

Statistical analysis

, mm r r r m r,r_ r r , m r r• m r fr m r 6 f r f m r • f , •_f_• , r fr m m r f fr m ¢ f ¢ r 6 fr m r r 🛭 rr 6 fr , r 6 f r rr 6 6 r r 6 r 🕻 r 6, • r 6, ff frr. 6 r 6 mr r r ¢, r r , r m r r , r f f r r. 6 6 6 6 • f • r r. 6 r r f . m/ r , r m r r. r . r rr f , r r 6 r rf • % • f 6 r r r 6 r , f r r r . r , f •

,

Results


Patient characteristics

r r m f r f , m \mathbf{m} r 🕻 . 6 Table 3 , mm r r m % r r r f m % r r m _, r rm r %, r , f % r r r_ r 6 m % m e re % % m r , 6 • r f • r r r 🛭 r r r 6 r . r , % % . r , fr•r r 6 , f f • r r 6 6 6 r s, rr 6 6 f m r 🛭 rr 6 , r f r 6 r 🗣 rr 6 r

Tamura M, et al.

r • r_ •		f % rm r.		
1 * 1	-		1	
, m				
. r				
	-	-		
r	~	~		
	~ %	%		
m	%	%		
. m				
m r	67	<i>61</i>		
m r		_% 		
m r	%	%		
/ C_ \$ T \$ / T	07	07		
rr •_	% 01-	% 		
≥ • m	%	70		
m _ • _	07	07		
	% %	% %		
	%	% %		
	% %			
	70	_ %		
	_%	%		
¢r¢_m	70 %			
′ m′ € €r€_ m r	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	70 %0		
^r mr_ ¢m	70	70		
-				
-				
·	%	%		
	%	%		
	%	%		
	%	%		
	%	%		
	%	%		
	%	%		
	%	%		
m . • .				
	%	%		
	%	%		
67 f				
	%	%		
	%	%		
، ۲				
	%	%		
	%	%		
r rerre				
	%	%		
	%	%		

Table 3 Demographic and clinical characteristics by the CONUT score group



____r, & frenre e ferenre e fer___ren rerr

ROC curves of inflammatory markers for OS prediction

f r • r • r Fig. 1 r f r f r s, r r, r m 📢 ff fr fr • r fr f r fr f r • r % f 🕻 f r r r. r Table 4 r f ____f.• ff r fr m f r • r r _ r 6

Survival analysis based on CONUT score

		_ ≥ .r	r _ C r	_
	%	-	r.r.	¢ ,
	-	%	r m	
m	m	rfrm,r		
	• r	• r	f.•	r
r.			r,	

r /	r.r	r	%
%			_
Fig. 2	m	6	
	. ľ 1	rr.	-
_ •	r,	Fig. 3	-
% fr 1	n • • r		fr m
r	-	. ľ ,	
- %	frm,.•	¢ r	%
r r		. r ,	

Prognostic value of CONUT score and other clinicopathological variables

r m Table 5 r. f r m . . , m , r 6 f ¢ r rm f m, r 6 m 6 r r % • r L 1 rf, •mrrfr r. r. •mr r c r f r % Table 6 . 6 1. r 1

Discussion

r, r r f m m r f • r rr. • r r, m r. . , r. r •• r _ . fr r r. r,r r 6 f m f • r • m r m , r_ r

mr_r frmr, . • •r r . r ır. r r r r r , m r r 6 r , , ff • ffr r m . <u>r</u> <u>r</u> , 6 6 r fr_ f • r • r r m 6 f ff r 6 1 I. _ 6 r m • r 1. 6 m r r r r r rmr f • m r . . . r r r r / ľ._¢ r. _ _ . r

r r

	f mm	r _				
	, ff ,	-	%	1		
-			-			
			-			
			_			
-			-			
			-			
-			_			
_			_			
			-			
			-			

Table 4 Comparison of the AUC between the CONUT score and other systemic inflammatory factors

r • r r . , r. r , r • f r 6 , , r r. 6 r_ r_• / r_ r r r r m , m r m . _ , m m r_ r ¢ r 6 6 , r m m 6 r m r r

, r _ _ , m_ r





Fig. 2 r 🖬 r fr A B С___ r •• r r r • rr • fr efe , r , r m ۲r _ r . , r . ,

r r , _ _ r • , sr, f m. f mm r_ r. _€f € r__ 1 r. 🤇 • m r_, • • r f • f_/f/rr r r r • m r • . · r . 6 f. • • r _ r _ r • r . . rr.r r_rr f 🗤 r• r _ / r f fmm rr r fmm rmrr 6 • r _ r _ _ r _ m / r_ _ fr r r n r m . 6 6 , . mrrm r r r 6, 6 6

m r r r f f r. 6 fr _m/ , r. ۳

• r r. r. _ r r

• r





	r			, _ f				
ľ_		%		,			%	,
r m					_		_	
≥								
m , , r								
≥								
rr_€r€rr≥								
m a ca ≥								
• r• m								
, _€ , ≥								
. • r ≥			-		_			-
r,r_r_	¢ f ¢	r	m		r	mr		

_ r _ , r _ ,

Table 6 Univariate and multivariate Cox proportional hazards regression analyses for OS. Subgroup analysis in pathological stage I

_	r			, <u>r</u>			
r_		%	,	%	,		
r m							
\geq							
m , , r							
≥							
, <u>r</u> . € , <u>r</u> ≥							
• r• m							
-							
_ • r ≥		_	-				

r 'r r r f f r m r mr r

• /• /r_. r /r_• r . r m _____f, ___¢r ____mrrf_rr._¢,¢m - ' r r ' **s** rr_r, r, f, _ . r · _ r . r r f

r sr fr sr r . r r m r fr m r . s s r r f f frm r re, e, f , e, f , m • f. r ... • f r r•__f__r••r rm r ¢ f ¢ m r f ¢ _ • r · · r · . 6 er <u>f</u>er.efer _ • r _'r mrfer _err 'm_ , ¢___ ¢ ľ ____mrrfr r_•____r

m_r **f** • m r , m m • r • r • , r · _ m r m r r _ r _ r m f

_ •r _ r _ r _ _ • r r . .

rr • . , rf . . • r. . . **6** m fr

. f. r. r 6 r

Conclusion

rr____¢r¢ , fr s rfr. r ______ r___ r______ • · _ · _ f · r _ f fr, r. r fr r rm rr. rr. r r m m 6 r_mr___rm

Declarations

Ethical approval

r r • mm f 6 _ _ 6 _ 6

Consent for publication

. 6

Data availability

fr_r_r

Author contributions

_ **6** , _ _ r_• r_•. rf m, «r_ с т с б Г. . . б Г. . . . т Г • r_ / r fm, «r

Funding

6

Conflicts of interest/Competing interests

r f_f_r r

References

- . r r. . . m f r. **fer** ir.e r r r r 87 r m • f m 77
- 37 , m _____mrr_fr r. e. e. n. m. / r. 214
- r « r « « r « 10 ____

r _ m / . r _ . / r _ . • r _ r. _•mrr_m_••r• • • r _ r • _ . fr _ • m r • • r 38 m_m_, _____ m_f_mm_r_r , m r

mrrr_•r_r__r ¢r • • • • • • • m ____ 11

m r . _• m • r _ _ 6 m • r _ • • • • r _ f mm _ r _ • r = 8 _
 i
 ff
 f
 f
 f

 i
 m
 r
 f
 f
 f

 i
 m
 r
 f
 f
 f

 i
 m
 r
 f
 f
 f

 i
 m
 f
 f
 f
 f
 • m • f r • _ r _ m • r _ _ m • , • • r r •rm• rr 6 ... m f r rerrrrr. f

•f•r

• m _• _ •. r r • m • • • r r / r 46

m m fımrr frr r......

r **c c r** 35

_m _f •rr . fr. f.r. fr. . fr. r

m/r/m ferfr r_'r_rferfr 4 r • m • r e e

m_€_fmm__ r.__€€r € f r_€ 6 39

r. . m m/ **9**

r _ · r _ _ 20 _ _ _ 1 fr• r _ , r_ · • r · r . • m r r r•__fr_•mr

• r _ 23